CYTK Cytokinetics, Incorporated - Common Stock
$76,68
Precio · Ago 19, 2026
Fundamentales a fecha de Ago 6, 2026
Rango 52S
$35–$88
78% of range
Calificación del Analista
BUY
28 analysts
Precio Objetivo
$110
+43% upside
P/E (TTM)
-11.7
ROE
152.7%
Margen de Beneficio Neto
-891.6%
Acerca de Cytokinetics, Incorporated - Common Stock Descripción general de la empresa de Wikipedia
Cytokinetics, Incorporated, is a biopharmaceutical company based in South San Francisco, California, that develops muscle activators and muscle inhibitors as potential treatments for people with diseases characterized by impaired or declining muscle function.
Leer más
Cytokinetics, Incorporated, is a biopharmaceutical company based in South San Francisco, California, that develops muscle activators and muscle inhibitors as potential treatments for people with diseases characterized by impaired or declining muscle function.
History
Cytokinetics was founded in 1997 by James Spudich, Ronald Vale, James Sabry and Lawrence S.B. Goldstein, four scientists at Stanford, UCSD, and UCSF. Operations began in 1998.
Initially, Cytokinetics focused on the possible pharmacological targets and areas of application of drugs based on cytoskeletal proteins. Eventually, the company narrowed its focus to the mechanics of muscle biology. Cytokinetics develops muscle activators and muscle inhibitors to improve muscle function in patients with cardiovascular and neuromuscular diseases.
In 2004 the company completed its initial public offering (IPO).
In January 2007, Cytokinetics named Robert I. Blum as president and CEO. Prior to this, Blum has been involved in the company since its founding, with roles in business development, corporate development and R&D.
In 2013, Cytokinetics finalized a licensing and discovery deal with Astellas to research treatment for muscle weakness and fatigue.
In July 2020, Ji Xing Pharmaceuticals signed a financing deal with Cytokinetics, which included the rights to commercialize the drug designed to treat hypertrophic cardiomyopathies, aficamten, in China and certain neighboring regions.
Products
Omecamtiv mecarbil is a cardiac muscle activator for the potential treatment of heart failure. In May 2020, omecamtiv mecarbil was granted fast track designation by the FDA for the treatment of chronic HF with reduced ejection fraction. Amgen purchased an option on omecamtiv mecarbil in 2006, and the two companies extended their partnership several times. In June 2013, Cytokinetics and Amgen expanded their licensing deal for omecamtiv mecarbil to include Japan. In November 2020 Amgen elected to terminate the collaboration, effective May 20, 2021, and Cytokinetics regained worldwide rights to develop and commercialize omecamtiv mecarbil.
Reldesemtiv (previously known as CK-2127107) is a next-generation fast skeletal muscle troponin activator (FSTA) that has undergone clinical trials for ALS.
Aficamten (previously known as CK-3773274) is an oral, small-molecule myosin inhibitor, to treat hypertrophic cardiomyopathy (HCM).
Fuente: Wikipedia (Inglés), CC BY-SA 4.0 · Ver en Wikipedia ↗
CYTK Instantánea de la Acción Precio, capitalización bursátil, P/E, BPA, ROE, deuda/capital, rango de 52 semanas
Precio
$76.67
Capitalización Bursátil
$9.43B
P/E (TTM)
-11.7
BPA (TTM)
$-6.54
Ingresos (TTM)
$88M
Rendimiento div.
—
ROE
152.7%
Deuda/Capital
-0.4
Rango 52S
$35 – $88
CYTK Gráfico del Precio de la Acción OHLCV diario con indicadores técnicos — desplace, amplíe y personalice su vista
Configure
Rendimiento a 10 años Tendencias de ingresos, beneficio neto, márgenes y BPA
Ingresos y Beneficio Neto
$88M
2016-12-31
→
2025-12-31
BPA
$-6.54
2016-12-31
→
2025-12-31
Flujo de caja libre
$-535M
2016-12-31
→
2025-12-31
Márgenes
-891.6%
Valoración Ratios P/E, P/S, P/B, EV/EBITDA: ¿está la acción cara o barata?
Métrica
Tendencia a 5 años
CYTK
Mediana de Pares
P/E (TTM)
-11.7
28.5
P/S (TTM) (P/V (TTM))
107.1
20.1
P/B (P/C)
-14.3
12.9
EV / EBITDA
-15.9
—
Price / FCF (Precio / FCF)
-17.6
—
Rentabilidad Márgenes brutos, operativos y netos; ROE, ROA, ROIC
Métrica
Tendencia a 5 años
CYTK
Mediana de Pares
Operating Margin (Margen Operativo)
-695.4%
—
Net Profit Margin (Margen de Beneficio Neto)
-891.6%
-48.4%
ROA
-55.5%
-28.4%
ROE
152.7%
-49.2%
Salud financiera Deuda, liquidez, solvencia — solidez del balance general
Métrica
Tendencia a 5 años
CYTK
Mediana de Pares
Debt / Equity (Deuda / Patrimonio)
-0.4
—
Current Ratio (Ratio corriente)
4.5
5.0
Quick Ratio (Ratio Rápido)
0.7
—
Crecimiento Crecimiento de ingresos, BPA y beneficio neto: interanual, CAGR a 3 años, CAGR a 5 años
Métrica
Tendencia a 5 años
CYTK
Mediana de Pares
Revenue YoY (Ingresos interanuales)
376.6%
—
Revenue CAGR 3Y (Ingresos CAGR 3A)
-2.4%
—
Revenue CAGR 5Y (Ingresos CAGR 5A)
9.5%
—
Eficiencia de capital Rotación de activos, rotación de inventario, rotación de cuentas por cobrar
Métrica
Tendencia a 5 años
CYTK
Mediana de Pares
CYTK Consenso de analistas Opiniones de analistas alcistas y bajistas, precio objetivo a 12 meses, potencial alcista
COMPRA
28 analistas
- Compra fuerte 6 21,4%
- Compra 19 67,9%
- Mantener 3 10,7%
- Venta 0 0,0%
- Venta fuerte 0 0,0%
Precio objetivo a 12 meses
20 analistas · 2026-08-18
Mediana
$107.50
← Por Debajo de Todos los Objetivos
$76.67
Mín
$85.00
Máx
$146.00
Objetivo mediano
$107.50
+40,2%
Objetivo medio
$109.90
+43,3%
Historial de Ganancias EPS real vs estimado, sorpresa %, tasa de aciertos, próxima fecha de resultados
Sorpresa Media
-0.08%
| Período | EPS Actual | EPS est. | Sorpresa |
|---|---|---|---|
| 30 de junio de 2026 | $-1.50 | $-1.67 | 0.17% |
| 31 de marzo de 2026 | $-1.67 | $-1.69 | 0.02% |
| 31 de diciembre de 2025 | $-1.50 | $-1.49 | -0.01% |
| 30 de septiembre de 2025 | $-2.55 | $-1.61 | -0.94% |
| 30 de junio de 2025 | $-1.12 | $-1.41 | 0.28% |
| 31 de marzo de 2025 | $-1.39 | $-1.41 | 0.02% |
Comparación de pares (subindustria GICS) Métricas clave frente a competidores del sector
| Ticker | Capitalización Bursátil | P/E | Ingresos interanuales | Margen Neto | ROE | Margen Bruto |
|---|---|---|---|---|---|---|
| CYTK | $7.81B | -9.7 | 376.6% | -891.6% | 152.7% | — |
| ARWR | $4.68B | -3449.0 | 23258.2% | -0.20% | -0.50% | — |
| MDGL | $13.30B | -45.3 | 432.1% | -30.1% | -44.4% | — |
| HALO | $7.93B | 26.3 | 37.5% | 22.7% | 166.1% | — |
| PRAX | $7.43B | -21.9 | 249.5% | — | -47.3% | — |
| APGE | $5.16B | -17.9 | — | — | — | — |
| PTGX | $5.47B | -42.6 | -89.4% | -282.8% | -20.3% | — |
| KRYS | $7.20B | 36.0 | 33.9% | 52.6% | 18.1% | — |
| KYMR | $6.33B | -21.1 | -16.7% | -794.0% | -24.4% | — |
| SMMT | $13.56B | -12.1 | — | — | -235.1% | — |
Fundamentales Completos Todas las métricas por año — estado de resultados, balance general, flujo de caja
Estado de resultados 16
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $88M | $18M | $8M | $95M | $70M | $56M | $27M | $32M | $13M | $106M | $29M | $47M | |
| R&D Expense | $416M | $339M | $330M | $241M | $160M | $97M | $86M | $89M | $90M | $60M | $46M | $44M | |
| SG&A Expense | $284M | $215M | $174M | $178M | $97M | $53M | $40M | $31M | $36M | $28M | $20M | $17M | |
| Operating Expenses | $700M | $555M | $504M | $419M | $257M | $150M | $126M | $120M | $127M | $88M | $66M | $62M | |
| Operating Income | $-612M | $-536M | $-496M | $-324M | $-186M | $-94M | $-99M | $-89M | $-113M | $19M | $-37M | $-15M | |
| Interest Expense | $46M | $38M | $28M | $19M | $16M | $16M | $7M | $4M | $3M | $3M | $268.0K | $0 | |
| Interest Income | · | · | · | $11M | $1M | $5M | $4M | $4M | · | $449.0K | $156.0K | $101.0K | |
| Other Non-op | $48M | $52M | $28M | $11M | $331.0K | $5M | $5M | $4M | $3M | $464.0K | $174.0K | $108.0K | |
| Pretax Income | · | · | · | · | · | · | · | $-106M | $-128M | $16M | $-38M | $-15M | |
| Income Tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | |
| Net Income | $-785M | $-590M | $-526M | $-389M | $-215M | $-127M | $-122M | $-106M | $-128M | $16M | $-38M | $-15M | |
| EPS (Basic) | $-6.54 | $-5.26 | $-5.45 | $-4.33 | $-2.80 | $-1.97 | · | · | $-2.59 | $0.41 | $-0.97 | $-0.41 | |
| EPS (Diluted) | $-6.54 | $-5.26 | $-5.45 | $-4.33 | $-2.80 | $-1.97 | · | · | $-2.59 | $0.39 | $-0.97 | $-0.41 | |
| Shares (Basic) | 120,103 | 111,979 | 96,524 | 89,825 | 76,886 | 64,524 | · | · | 49,404,000 | 39,943,000 | 38,814,000 | 35,709,000 | |
| Shares (Diluted) | 120,103 | 111,979 | 96,524 | 89,825 | 76,886 | 64,524 | · | · | 49,404,000 | 42,561,000 | 38,814,000 | 35,709,000 | |
| EBITDA | $-602M | $-527M | $-484M | $-318M | $-184M | $-92M | $-98M | $-88M | $-111M | $19M | $-37M | $-14M |
Balance general 26
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $123M | $95M | $113M | $66M | $113M | $83M | $36M | $42M | $125M | $67M | $65M | $20M | |
| Receivables | $18M | $17M | $1M | $147.0K | $52M | $4M | $5M | $2M | $1M | $24.0K | · | · | |
| Inventory | $0 | · | · | · | · | · | · | · | · | · | · | · | |
| Prepaid Expense | $17M | $15M | $12M | $12M | $12M | $6M | $3M | $2M | $4M | $2M | $2M | $1M | |
| Other Current Assets | · | · | · | · | · | · | · | · | · | · | · | $1M | |
| Current Assets | $917M | $1.11B | $628M | $795M | $536M | $474M | $234M | $208M | $274M | $159M | $113M | $131M | |
| PP&E (Net) | $79M | $66M | $69M | $80M | $73M | $13M | $5M | $3M | $4M | $4M | $2M | $2M | |
| PP&E (Gross) | $126M | $103M | $97M | $98M | $89M | $38M | $29M | $27M | $26M | $25M | $23M | $22M | |
| Accum. Depreciation | $47M | $37M | $28M | $17M | $16M | $25M | $24M | $24M | $23M | $21M | $21M | $20M | |
| Other Non-current Assets | $17M | $8M | $8M | $10M | $7M | $6M | · | $300.0K | $429.0K | $200.0K | $200.0K | $200.0K | |
| Total Assets | $1.42B | $1.40B | $824M | $1.01B | $841M | $534M | $290M | $211M | $295M | $170M | $115M | $133M | |
| Accounts Payable | $22M | $20M | $22M | $26M | $21M | $8M | $8M | $4M | $5M | $4M | $2M | $1M | |
| Accrued Liabilities | $83M | $55M | $43M | $44M | $34M | $19M | $12M | $16M | $17M | $18M | $8M | $5M | |
| Current Liabilities | $202M | $180M | $103M | $85M | $72M | $31M | $26M | $22M | $32M | $33M | $32M | $24M | |
| Capital Leases | $108M | $113M | $120M | $127M | $112M | $440.0K | $2M | $771.0K | · | · | · | · | |
| Other Non-current Liabilities | · | $0 | $186.0K | $1M | $4M | $0 | · | $771.0K | $1M | $142.0K | · | · | |
| Total Liabilities | $2.08B | $1.54B | $1.21B | $1.12B | $597M | $420M | $301M | $185M | $185M | $76M | $47M | $41M | |
| Long-term Debt | $288M | $620M | $639M | $650M | · | $46M | $45M | $42M | $32M | $30M | $15M | · | |
| Total Debt | $288M | $105M | $68M | $64M | $47M | $46M | $45M | $42M | $32M | $30M | $15M | · | |
| Common Stock | $123.0K | $118.0K | $102.0K | $94.0K | $84.0K | $70.0K | $59.0K | $55.0K | $54.0K | $41.0K | $40.0K | $39.0K | |
| Paid-in Capital | · | · | · | · | $1.45B | · | · | · | · | · | · | $589M | |
| Retained Earnings | $-3.49B | $-2.70B | $-2.11B | $-1.59B | $-1.21B | $-992M | $-865M | $-743M | $-646M | $-518M | $-535M | $-497M | |
| AOCI | $630.0K | $2M | $-10.0K | $-4M | $-869.0K | $149.0K | $679.0K | $500.0K | $343.0K | $137.0K | $149.0K | $-4.0K | |
| Stockholders' Equity | $-660M | $-135M | $-386M | $-108M | $244M | $113M | $-11M | $26M | $110M | $94M | $69M | $92M | |
| Liabilities + Equity | $1.42B | $1.40B | $824M | $1.01B | $841M | $534M | $290M | $211M | $295M | $170M | $115M | $133M | |
| Shares Outstanding | 122,943,172 | 118,209,139 | 101,637,922 | 94,833,975 | 84,799,542 | 71,015,183 | 59,172,124 | 54,717,906 | 53,960,832 | 40,646,595 | 39,581,692 | 38,659,738 |
Flujo de Efectivo 16
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $10M | $10M | $12M | $6M | $2M | $2M | $1M | $1M | $2M | $741.0K | $589.0K | $490.0K | |
| Stock-based Comp | $112M | $98M | $72M | $48M | $27M | $18M | $11M | $10M | $9M | $7M | $5M | $3M | |
| Deferred Tax | · | · | · | · | · | · | · | · | · | $0 | $0 | $0 | |
| Restructuring | · | · | · | · | · | · | · | · | · | · | · | $0 | |
| Other Non-cash | $153M | $86M | $28M | $36M | $44M | $117M | $19M | $-6M | $15M | $13M | $37M | $-34M | |
| Operating Cash Flow | $-510M | $-396M | $-414M | $-300M | $-143M | $9M | $-91M | $-101M | $-102M | $37M | $5M | $-45M | |
| CapEx | $25M | $4M | $1M | $11M | $49M | $11M | $3M | $889.0K | $3M | $2M | $562.0K | $1M | |
| Investing Cash Flow | $17M | $-553M | $239M | $-262M | $-148M | $-197M | $-75M | $5M | $-66M | · | · | · | |
| Net Debt Issued | $-11M | $-9M | · | $-48M | · | · | · | · | · | · | · | · | |
| Stock Issued | · | · | $164M | · | $0 | $0 | $36M | $0 | $112M | $0 | $9M | $49M | |
| Net Stock Activity | · | · | $164M | · | $0 | $0 | $36M | $0 | $112M | $0 | $9M | $49M | |
| Financing Cash Flow | $524M | $931M | $221M | $516M | $320M | $234M | $160M | $13M | $226M | · | · | · | |
| Net Change in Cash | $30M | $-18M | $46M | $-45M | $30M | $47M | $-6M | $-83M | $58M | $2M | $45M | $57.0K | |
| Taxes Paid | $0 | $0 | $0 | · | · | · | · | $1.0K | $1.0K | $1.0K | $1.0K | $1.0K | |
| Free Cash Flow | $-535M | $-400M | $-416M | $-311M | $-191M | $-2M | $-94M | $-102M | $-105M | $35M | $4M | $-46M | |
| Levered FCF | · | · | · | · | · | · | · | $-106M | $-108M | $33M | · | $-46M |
Rentabilidad 7
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -695.4% | -2902.7% | -6589.7% | -342.8% | -264.5% | -168.3% | -368.0% | -282.3% | -848.3% | 17.6% | -130.5% | -31.4% | |
| Net Margin | -891.6% | -3191.1% | -6988.6% | -411.2% | -305.7% | -228.0% | -452.9% | -337.4% | -955.9% | 15.5% | -130.9% | -31.2% | |
| Pretax Margin | · | · | · | · | · | · | · | -337.4% | -955.9% | 15.5% | -130.9% | -31.2% | |
| EBITDA Margin | -683.9% | -2851.1% | -6431.8% | -336.6% | -261.3% | -165.0% | -363.2% | -278.3% | -833.9% | 18.3% | -128.5% | -30.4% | |
| ROA | -55.5% | -53.0% | -57.2% | -41.9% | -31.3% | -30.9% | -48.6% | -42.0% | -55.0% | 11.5% | -30.2% | -13.6% | |
| ROE | 152.7% | 789.8% | 127.6% | 628.0% | -87.4% | -96.8% | 790.0% | -272.5% | -125.2% | 20.2% | -46.7% | -20.0% | |
| ROIC | · | · | · | · | · | · | · | -130.1% | -80.1% | 15.0% | -44.9% | -16.0% |
Liquidez y Solvencia 5
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 4.5 | 6.2 | 6.1 | 9.4 | 7.5 | 15.2 | 9.0 | 9.4 | 8.5 | 4.8 | 3.6 | 5.5 | |
| Quick Ratio | 0.7 | 0.6 | 1.1 | 0.8 | 2.3 | 2.8 | 1.6 | 2.0 | 3.9 | 2.0 | 2.1 | 0.8 | |
| Debt / Equity | -0.4 | -0.8 | -0.2 | -0.6 | 0.2 | 0.4 | -4.1 | 1.6 | 0.3 | 0.3 | 0.2 | · | |
| LT Debt / Equity | -0.4 | -0.7 | -0.2 | -0.6 | 0.2 | 0.4 | -4.1 | 1.5 | 0.3 | 0.3 | 0.2 | · | |
| Interest Coverage | -13.4 | -14.2 | -17.5 | -16.7 | -11.3 | -5.9 | -14.9 | -23.4 | -37.6 | 6.9 | · | · |
Eficiencia 2
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.1 | 0.0 | 0.0 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.7 | 0.2 | 0.4 | |
| Receivables Turnover | 5.1 | 2.1 | 10.5 | 3.6 | 2.5 | 11.7 | 7.3 | 18.8 | 23.5 | · | · | · |
Tasas de Crecimiento 3
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 376.6% | 145.3% | -92.0% | 34.3% | 26.2% | · | · | · | · | · | · | · | |
| Revenue CAGR 3Y | -2.4% | -36.0% | -48.7% | · | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 9.5% | · | · | · | · | · | · | · | · | · | · | · |
Valoración (TTM) 14
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $88M | $18M | $8M | $95M | $70M | $56M | $27M | $32M | $13M | $106M | $29M | $47M | |
| Net Income TTM | $-785M | $-590M | $-526M | $-389M | $-215M | $-127M | $-122M | $-106M | $-128M | $16M | $-38M | $-15M | |
| Market Cap | $7.81B | $5.56B | $8.49B | $4.35B | $3.87B | $1.48B | $628M | $346M | $440M | $494M | $414M | $310M | |
| Enterprise Value | $7.98B | $5.57B | $8.44B | $4.34B | $3.80B | $1.44B | $636M | $346M | $346M | $457M | $364M | · | |
| P/E | -9.7 | -8.9 | -15.3 | -10.6 | -16.3 | -10.5 | · | · | -3.1 | 31.2 | -10.8 | -19.5 | |
| P/S | 88.7 | 301.0 | 1126.9 | 45.9 | 54.9 | 26.4 | 23.4 | 11.0 | 32.9 | 4.6 | 14.4 | 6.6 | |
| P/B | -11.8 | -41.1 | -22.0 | -40.3 | 15.8 | 13.0 | -57.4 | 13.3 | 4.0 | 5.2 | 6.0 | 3.4 | |
| P / Tangible Book | · | · | · | · | 15.8 | 13.0 | · | · | · | · | · | · | |
| P / Cash Flow | -15.3 | -14.0 | -20.5 | -14.5 | -27.1 | 165.0 | -6.9 | -3.4 | -4.3 | 13.4 | 84.8 | -6.9 | |
| P / FCF | -14.6 | -13.9 | -20.4 | -14.0 | -20.2 | -699.7 | -6.7 | -3.4 | -4.2 | 14.0 | 95.8 | -6.7 | |
| EV / EBITDA | -13.2 | -10.6 | -17.4 | -13.6 | -20.6 | -15.6 | -6.5 | -3.9 | -3.1 | 23.5 | -9.9 | · | |
| EV / FCF | -14.9 | -13.9 | -20.3 | -14.0 | -19.9 | -682.3 | -6.8 | -3.4 | -3.3 | 12.9 | 84.1 | · | |
| EV / Revenue | 90.6 | 301.5 | 1121.0 | 45.9 | 54.0 | 25.8 | 23.7 | 11.0 | 25.9 | 4.3 | 12.7 | · | |
| Earnings Yield | -10.3% | -11.2% | -6.5% | -9.4% | -6.1% | -9.5% | · | · | -31.8% | 3.2% | -9.3% | -5.1% |
Estado de resultados 14
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $29M | $19M | $18M | $2M | $67M | $2M | $17M | $463.0K | $249.0K | $835.0K | $2M | $378.0K | $867.0K | $5M | $2M | $3M | |
| R&D Expense | $98M | $96M | $104M | $99M | $110M | $98M | $94M | $85M | $80M | $82M | $85M | $83M | $83M | $79M | $75M | $63M | |
| SG&A Expense | $104M | $105M | $92M | $69M | $66M | $57M | $62M | $57M | $51M | $46M | $44M | $40M | $40M | $50M | $54M | $48M | |
| Operating Expenses | $208M | $203M | $196M | $169M | $178M | $157M | $156M | $141M | $130M | $127M | $129M | $123M | $123M | $129M | $129M | $111M | |
| Operating Income | $-179M | $-184M | $-178M | $-167M | $-112M | $-156M | $-139M | $-141M | $-130M | $-126M | $-127M | $-122M | $-122M | $-124M | $-127M | $-108M | |
| Interest Expense | · | · | $14M | $11M | $11M | · | $9M | $9M | $13M | $7M | $7M | $7M | $7M | $7M | $7M | $7M | |
| Interest Income | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | $4M | |
| Other Non-op | $14M | $11M | $11M | $10M | $13M | $14M | $15M | $17M | $12M | $8M | $8M | $7M | $7M | $6M | $6M | $4M | |
| Net Income | $-199M | $-206M | $-183M | $-306M | $-134M | $-161M | $-150M | $-161M | $-143M | $-136M | $-137M | $-129M | $-129M | $-131M | $-137M | $-142M | |
| EPS (Basic) | $-1.50 | $-1.67 | $-1.51 | $-2.55 | $-1.12 | $-1.36 | $-1.26 | $-1.36 | $-1.31 | $-1.33 | $-1.38 | $-1.35 | $-1.34 | $-1.38 | $-1.53 | $-1.52 | |
| EPS (Diluted) | $-1.50 | $-1.67 | $-1.51 | $-2.55 | $-1.12 | $-1.36 | $-1.26 | $-1.36 | $-1.31 | $-1.33 | $-1.38 | $-1.35 | $-1.34 | $-1.38 | $-1.53 | $-1.52 | |
| Shares (Basic) | 132,086 | 123,273 | -237,832 | 119,982 | 119,457 | 118,496 | -216,870 | 117,685 | 109,240 | 101,924 | -190,466 | 96,071 | 95,755 | 95,164 | -174,660 | 93,758 | |
| Shares (Diluted) | 132,086 | 123,273 | -237,832 | 119,982 | 119,457 | 118,496 | -216,870 | 117,685 | 109,240 | 101,924 | -190,466 | 96,071 | 95,755 | 95,164 | -174,660 | 93,758 | |
| EBITDA | $-179M | $-180M | · | $-167M | $-112M | $-153M | · | $-141M | $-130M | $-124M | · | $-122M | $-122M | $-123M | · | $-108M |
Balance general 24
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $255M | $130M | $123M | $225M | $75M | $74M | $95M | $47M | $190M | $120M | · | $100M | $69M | $102M | · | $106M | |
| Receivables | $24M | $7M | $18M | $2M | $8M | $2M | $17M | $244.0K | $0 | $834.0K | · | $2M | $985.0K | $1M | · | $2M | |
| Inventory | $380.0K | $154.0K | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| Prepaid Expense | $18M | $14M | $17M | $13M | $20M | $16M | $15M | $7M | $11M | $19M | · | $20M | $20M | $16M | · | $14M | |
| Current Assets | $1.21B | $839M | $917M | $977M | $887M | $956M | $1.11B | $1.02B | $1.07B | $639M | · | $561M | $587M | $681M | · | $884M | |
| PP&E (Net) | $79M | $82M | $79M | $76M | $70M | $67M | $66M | $64M | $66M | $68M | · | $76M | $77M | $79M | · | $80M | |
| PP&E (Gross) | · | · | $126M | · | · | · | $103M | · | · | · | · | · | · | · | · | · | |
| Accum. Depreciation | · | · | $47M | · | · | · | $37M | · | · | · | · | · | · | · | · | · | |
| Other Non-current Assets | $19M | $18M | $17M | $17M | $15M | $13M | $8M | $8M | $8M | $8M | · | $8M | $8M | $8M | · | · | |
| Total Assets | $1.92B | $1.27B | $1.42B | $1.44B | $1.23B | $1.26B | $1.40B | $1.44B | $1.52B | $808M | · | $741M | $780M | $890M | · | $1.08B | |
| Accounts Payable | $21M | $25M | $22M | $22M | $16M | $14M | $20M | $12M | $9M | $13M | · | $14M | $13M | $17M | · | $14M | |
| Accrued Liabilities | $77M | $69M | $83M | $62M | $52M | $43M | $55M | $50M | $40M | $40M | · | $33M | $31M | $36M | · | $40M | |
| Current Liabilities | $181M | $199M | $202M | $142M | $131M | $160M | $180M | $110M | $103M | $89M | · | $78M | $66M | $75M | · | $76M | |
| Capital Leases | $102M | $105M | $108M | $111M | $111M | $113M | $113M | $115M | $117M | $119M | · | $122M | $124M | $125M | · | $114M | |
| Other Non-current Liabilities | · | · | · | $2M | $2M | $3M | · | $0 | $0 | $2.0K | · | $408.0K | $625.0K | $837.0K | · | $1M | |
| Total Liabilities | $2.10B | $2.10B | $2.08B | $1.96B | $1.59B | $1.53B | $1.54B | $1.45B | $1.42B | $1.20B | · | $1.18B | $1.11B | $1.12B | · | $1.09B | |
| Long-term Debt | $276M | $292M | $288M | $1.00B | $610M | $610M | $105M | $620M | $629M | $630M | · | · | · | · | · | · | |
| Total Debt | $276M | $292M | · | $176M | $173M | $105M | · | $105M | $104M | $68M | · | $61M | $62M | $64M | · | $64M | |
| Common Stock | $138.0K | $124.0K | $123.0K | $122.0K | $119.0K | $119.0K | $118.0K | $118.0K | $117.0K | $105.0K | · | $94.0K | $94.0K | $94.0K | · | $93.0K | |
| Retained Earnings | $-3.89B | $-3.69B | $-3.49B | $-3.30B | $-3.00B | $-2.86B | $-2.70B | $-2.55B | $-2.39B | $-2.25B | · | $-1.98B | $-1.85B | $-1.72B | · | $-1.45B | |
| AOCI | $-4M | $-2M | $630.0K | $34.0K | $-158.0K | $2M | $2M | $5M | $-1M | $-539.0K | · | $-874.0K | $-1M | $-2M | · | $-6M | |
| Stockholders' Equity | $-173M | $-827M | $-660M | $-521M | $-369M | $-266M | $-135M | $-14M | $109M | $-396M | $-386M | $-439M | $-333M | $-229M | $-108M | $-16M | |
| Liabilities + Equity | $1.92B | $1.27B | $1.42B | $1.44B | $1.23B | $1.26B | $1.40B | $1.44B | $1.52B | $808M | · | $741M | $780M | $890M | · | $1.08B | |
| Shares Outstanding | · | · | 122,943,172 | · | · | · | 118,209,139 | · | · | · | · | · | · | · | · | · |
Flujo de Efectivo 12
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $4M | $3M | $3M | $3M | $2M | $2M | $2M | $2M | $2M | $2M | $6M | $2M | $2M | $2M | $2M | $1M | |
| Stock-based Comp | $36M | $30M | $31M | $31M | $28M | $24M | $26M | $25M | $25M | $22M | $19M | $19M | $19M | $15M | $13M | $13M | |
| Other Non-cash | · | $27M | · | · | · | $4M | · | · | · | $-18M | · | · | · | $-8M | · | · | |
| Operating Cash Flow | $-160M | $-145M | $-143M | $-108M | $-128M | $-132M | $-66M | $-102M | $-99M | $-130M | $-74M | $-96M | $-122M | $-122M | $-98M | $-84M | |
| CapEx | $4M | $6M | $6M | $9M | $4M | $6M | $1M | $701.0K | $2M | $0 | $77.0K | $220.0K | $717.0K | $402.0K | $3M | $6M | |
| Investing Cash Flow | $-507M | $145M | $-71M | $-71M | $53M | $106M | $111M | $-45M | $-652M | $33M | $-81M | $73M | $82M | $165M | $29M | $-292M | |
| Net Debt Issued | · | $-3M | · | · | · | $-3M | · | · | · | $-705.0K | · | · | · | · | · | · | |
| Stock Issued | · | · | · | · | $0 | $0 | · | · | · | $94M | · | · | · | $0 | · | · | |
| Net Stock Activity | · | · | · | · | · | $0 | · | · | · | $94M | · | · | · | · | · | · | |
| Financing Cash Flow | $793M | $8M | $111M | $330M | $79M | $5M | $2M | $3M | $821M | $104M | $169M | $54M | $5M | $-7M | $30M | $389M | |
| Net Change in Cash | $125M | $7M | $-103M | $152M | $2M | $-21M | $48M | $-143M | $70M | $7M | $13M | $31M | $-34M | $36M | $-39M | $13M | |
| Free Cash Flow | · | $-151M | · | · | · | $-137M | · | · | · | $-130M | · | · | · | $-123M | · | · |
Rentabilidad 5
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -626.0% | -948.7% | · | -8613.4% | -167.0% | -9856.3% | · | -30410.6% | -52277.9% | -15118.0% | · | -32345.2% | -14077.2% | -2698.3% | · | -4311.8% | |
| Net Margin | -694.4% | -1064.5% | · | -15815.0% | -201.3% | -10220.1% | · | -34675.0% | -57557.4% | -16244.7% | · | -34238.6% | -14837.0% | -2846.1% | · | -5658.4% | |
| EBITDA Margin | -626.0% | -931.2% | · | -8613.4% | -167.0% | -9710.6% | · | -30410.6% | -52277.9% | -14838.8% | · | -32345.2% | -14077.2% | -2658.2% | · | -4311.8% | |
| ROA | -12.6% | -16.2% | · | -21.3% | -9.8% | -15.6% | · | -14.8% | -12.4% | -16.0% | · | -14.2% | -16.6% | -15.0% | · | -14.9% | |
| ROE | 73.3% | 37.7% | · | 114.5% | 103.3% | 48.7% | · | 70.9% | 127.6% | 43.4% | · | 56.9% | 116.1% | 232.9% | · | -122.1% |
Liquidez y Solvencia 5
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 6.7 | 4.2 | · | 6.9 | 6.8 | 6.0 | · | 9.3 | 10.4 | 7.2 | · | 7.2 | 8.9 | 9.0 | · | 11.6 | |
| Quick Ratio | 1.5 | 0.7 | · | 1.6 | 0.6 | 0.5 | · | 0.4 | 1.9 | 1.4 | · | 1.3 | 1.1 | 1.4 | · | 1.4 | |
| Debt / Equity | -1.6 | -0.4 | · | -0.3 | -0.5 | -0.4 | · | -7.5 | 1.0 | -0.2 | · | -0.1 | -0.2 | -0.3 | · | -4.0 | |
| LT Debt / Equity | -1.4 | -0.3 | · | -0.3 | -0.4 | -0.3 | · | -6.7 | 0.9 | -0.1 | · | -0.1 | -0.2 | -0.3 | · | -4.0 | |
| Interest Coverage | · | · | · | -14.7 | -10.1 | · | · | -15.8 | -10.2 | -17.8 | · | -17.1 | -17.3 | -17.9 | · | -15.9 |
Eficiencia 2
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | |
| Receivables Turnover | 1.7 | 4.4 | · | 1.9 | 15.9 | 1.1 | · | 0.3 | 0.5 | 0.9 | · | 0.2 | 0.6 | 1.3 | · | 1.7 |
Valoración (TTM) 4
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $117M | $90M | · | $71M | $69M | $3M | · | $2M | $2M | $7M | · | $8M | $97M | $97M | · | $98M | |
| Net Income TTM | $-845M | $-808M | · | $-762M | $-600M | $-601M | · | $-569M | $-537M | $-525M | · | $-532M | $-422M | $-383M | · | $-328M | |
| P/E | -12.5 | -9.8 | · | -8.6 | -6.4 | -7.5 | · | -9.9 | -10.2 | -13.0 | · | -5.3 | -7.3 | -8.4 | · | -12.9 | |
| Earnings Yield | -8.0% | -10.2% | · | -11.6% | -15.6% | -13.3% | · | -10.1% | -9.8% | -7.7% | · | -19.0% | -13.7% | -11.9% | · | -7.7% |
Estados Financieros Estado de resultados, balance general, flujo de caja — anual, últimos 5 años
Estado de resultados
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Ingresos | $88M | $18M | $8M | $95M | $70M |
| Margen Operativo % | -695.4% | -2902.7% | -6589.7% | -342.8% | -264.5% |
| Beneficio neto | $-785M | $-590M | $-526M | $-389M | $-215M |
| EPS Diluido | $-6.54 | $-5.26 | $-5.45 | $-4.33 | $-2.80 |
Balance general
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Deuda / Patrimonio | -0.4 | -0.8 | -0.2 | -0.6 | 0.2 |
| Ratio corriente | 4.5 | 6.2 | 6.1 | 9.4 | 7.5 |
| Ratio Rápido | 0.7 | 0.6 | 1.1 | 0.8 | 2.3 |
Flujo de Efectivo
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Flujo de caja libre | $-535M | $-400M | $-416M | $-311M | $-191M |
Últimas noticias Noticias recientes que mencionan a esta empresa
Mis Métricas Tu lista de seguimiento personal — filas seleccionadas de Fundamentales Completos
📊
Elige las métricas que te importan — haz clic en el ➕ junto a cualquier fila en Fundamentales Completos arriba.
Tu selección se guarda y te sigue en todos los tickers.
Propietarios institucionales (13F) 539 declarantes · $9.0B total · A fecha de 30 de junio de 2026
Instituciones que informan tener esta acción en su Formulario 13F trimestral de la SEC. Solo posiciones largas; un solo presentador puede aparecer dos veces para tramos de opciones separados. Las patas de put/call de compensación grandes suelen reflejar la creación de mercado o el inventario cubierto, no la convicción direccional.
Actividad institucional — Q2 2026 vs trimestre anterior
| Nuevas posiciones | Posiciones cerradas | Aumentado | Disminuido | Cambio neto de acciones |
|---|---|---|---|---|
| 104 (+7 vs trimestre anterior) | 49 (-8 vs trimestre anterior) | 222 (+45 vs trimestre anterior) | 112 (-32 vs trimestre anterior) | +17.8M |
Comparado con Q1 2026. Las presentaciones del Formulario 13F de la SEC vencen dentro de los 45 días posteriores al final del trimestre, más un pequeño margen para los presentadores tardíos; los trimestres que aún se encuentran dentro de esa ventana se omiten en favor del par más reciente completamente reportado.
| Institución | Valor | Acciones | % de 13F rastreadas | Tipo |
|---|---|---|---|---|
| VANGUARD PORTFOLIO MANAGEMENT LLC | $571 778 157 | 6 711 799 | 6,37% | Acciones |
| STATE STREET CORP | $553 243 709 | 6 494 233 | 6,16% | Acciones |
| VANGUARD CAPITAL MANAGEMENT LLC | $521 151 103 | 6 117 515 | 5,80% | Acciones |
| WELLINGTON MANAGEMENT GROUP LLP | $509 521 049 | 5 980 996 | 5,68% | Acciones |
| Avoro Capital Advisors LLC | $425 949 915 | 4 999 999 | 4,74% | Acciones |
| FMR LLC | $375 035 430 | 4 402 341 | 4,18% | Acciones |
| GEODE CAPITAL MANAGEMENT, LLC | $259 207 450 | 3 042 018 | 2,89% | Acciones |
| BANK OF AMERICA CORP /DE/ | $251 706 463 | 2 954 648 | 2,80% | Acciones |
| RTW INVESTMENTS, LP | $243 814 036 | 2 862 003 | 2,72% | Acciones |
| Polar Capital Holdings Plc | $191 988 358 | 2 253 649 | 2,14% | Acciones |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $161 060 214 | 1 890 600 | 1,79% | Opción de compra |
| Capital Research Global Investors | $143 683 584 | 1 686 625 | 1,60% | Acciones |
| WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC | $136 597 224 | 1 603 442 | 1,52% | Acciones |
| Integral Health Asset Management, LLC | $136 304 000 | 1 600 000 | 1,52% | Acciones |
| Point72 Asset Management, L.P. | $135 257 185 | 1 587 712 | 1,51% | Acciones |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $133 386 924 | 1 565 758 | 1,49% | Acciones |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $131 998 327 | 1 549 458 | 1,47% | Acciones |
| PRINCIPAL FINANCIAL GROUP INC | $111 435 932 | 1 308 087 | 1,24% | Acciones |
| Capital International Investors | $111 245 191 | 1 305 848 | 1,24% | Acciones |
| ARMISTICE CAPITAL, LLC | $106 487 500 | 1 250 000 | 1,19% | Opción de compra |
| ARMISTICE CAPITAL, LLC | $102 342 325 | 1 201 342 | 1,14% | Acciones |
| Pictet Asset Management Holding SA | $99 038 455 | 1 160 463 | 1,10% | Acciones |
| Frazier Life Sciences Management, L.P. | $98 810 092 | 1 159 879 | 1,10% | Acciones |
| Holocene Advisors, LP | $97 506 685 | 1 144 579 | 1,09% | Acciones |
| Woodline Partners LP | $93 769 315 | 1 100 708 | 1,04% | Acciones |
| NORGES BANK | $86 512 319 | 1 015 522 | 0,96% | Acciones |
| Royalty Pharma Sub-Manager, LLC | $83 519 594 | 980 392 | 0,93% | Acciones |
| NOMURA ASSET MANAGEMENT INTERNATIONAL INC. | $81 937 000 | 961 815 | 0,91% | Acciones |
| VANGUARD FIDUCIARY TRUST CO | $77 218 175 | 906 423 | 0,86% | Acciones |
| CITADEL ADVISORS LLC | $77 062 874 | 904 600 | 0,86% | Opción de compra |
| Melqart Asset Management (UK) Ltd | $65 385 455 | 767 525 | 0,73% | Acciones |
| Siren, L.L.C. | $64 655 121 | 758 952 | 0,72% | Acciones |
| Fisher Asset Management, LLC | $63 355 547 | 743 697 | 0,71% | Acciones |
| Foresite Capital Management IV, LLC | $60 884 867 | 714 695 | 0,68% | Acciones |
| Balyasny Asset Management L.P. | $60 599 821 | 711 349 | 0,67% | Acciones |
| Deep Track Capital, LP | $59 633 000 | 700 000 | 0,66% | Acciones |
| JANE STREET GROUP, LLC | $59 633 000 | 700 000 | 0,66% | Opción de compra |
| BNP PARIBAS FINANCIAL MARKETS | $58 702 470 | 689 077 | 0,65% | Acciones |
| Nationale-Nederlanden Powszechne Towarzystwo Emerytalne S.A. | $56 251 809 | 660 310 | 0,63% | Acciones |
| CITADEL ADVISORS LLC | $54 601 338 | 640 936 | 0,61% | Acciones |
| GOLDMAN SACHS GROUP INC | $54 053 311 | 634 503 | 0,60% | Acciones |
| Qube Research & Technologies Ltd | $48 774 257 | 572 535 | 0,54% | Acciones |
| EVENTIDE ASSET MANAGEMENT, LLC | $48 081 832 | 564 398 | 0,54% | Acciones |
| Affinity Asset Advisors, LLC | $46 854 500 | 550 000 | 0,52% | Acciones |
| First Turn Management, LLC | $44 930 228 | 527 412 | 0,50% | Acciones |
| AMERICAN CENTURY COMPANIES INC | $44 162 525 | 518 398 | 0,49% | Acciones |
| Caption Management, LLC | $43 651 356 | 512 400 | 0,49% | Opción de compra |
| D. E. Shaw & Co., Inc. | $40 874 247 | 479 801 | 0,46% | Acciones |
| Checkpoint Capital L.P. | $40 465 250 | 475 000 | 0,45% | Acciones |
| Hood River Capital Management LLC | $39 977 367 | 469 273 | 0,45% | Acciones |
| RP Management, LLC | $39 401 954 | 980 392 | 0,44% | Acciones |
| EMERALD ADVISERS, LLC | $39 013 272 | 457 956 | 0,43% | Acciones |
| ADAR1 Capital Management, LLC | $39 009 097 | 457 907 | 0,43% | Acciones |
| AMERIPRISE FINANCIAL INC | $38 010 006 | 446 179 | 0,42% | Acciones |
| Candriam S.C.A. | $37 708 477 | 443 066 | 0,42% | Acciones |
| MARSHALL WACE, LLP | $36 259 335 | 425 629 | 0,40% | Acciones |
| RHUMBLINE ADVISERS | $35 933 015 | 421 799 | 0,40% | Acciones |
| CITADEL ADVISORS LLC | $35 882 028 | 421 200 | 0,40% | Opción de venta |
| ALLIANCEBERNSTEIN L.P. | $35 327 299 | 535 993 | 0,39% | Acciones |
| GILDER GAGNON HOWE & CO LLC | $34 096 829 | 400 245 | 0,38% | Acciones |
| TD Asset Management Inc | $32 809 225 | 385 130 | 0,37% | Acciones |
| BlackRock, Inc. | $29 124 928 | 341 882 | 0,32% | Acciones |
| GSK plc | $29 001 573 | 340 434 | 0,32% | Acciones |
| TWO SIGMA INVESTMENTS, LP | $27 040 243 | 317 411 | 0,30% | Acciones |
| CITIGROUP INC | $26 852 314 | 315 205 | 0,30% | Acciones |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $24 671 024 | 289 600 | 0,27% | Opción de venta |
| Trails Edge Capital Partners, LP | $24 542 302 | 288 089 | 0,27% | Acciones |
| EMERALD MUTUAL FUND ADVISERS TRUST | $23 833 521 | 279 769 | 0,27% | Acciones |
| Polaris Capital Management, LLC | $22 737 211 | 266 900 | 0,25% | Acciones |
| SEGALL BRYANT & HAMILL, LLC | $21 899 197 | 257 063 | 0,24% | Acciones |
| Alyeska Investment Group, L.P. | $21 297 500 | 250 000 | 0,24% | Acciones |
| ExodusPoint Capital Management, LP | $21 234 374 | 249 259 | 0,24% | Acciones |
| Capital World Investors | $21 196 550 | 248 815 | 0,24% | Acciones |
| Walleye Capital LLC | $20 422 428 | 239 728 | 0,23% | Acciones |
| E. Ohman J:or Asset Management AB | $19 823 223 | 300 762 | 0,22% | Acciones |
| Sarissa Capital Management LP | $19 476 393 | 228 623 | 0,22% | Acciones |
| Swiss National Bank | $18 946 256 | 222 400 | 0,21% | Acciones |
| SPHERA FUNDS MANAGEMENT LTD. | $18 740 693 | 219 987 | 0,21% | Acciones |
| BAKER BROS. ADVISORS LP | $17 997 836 | 211 267 | 0,20% | Acciones |
| California Public Employees Retirement System | $17 979 520 | 211 052 | 0,20% | Acciones |
| Nicholas Investment Partners, LP | $17 810 758 | 209 071 | 0,20% | Acciones |
| PINNACLE ASSOCIATES LTD | $17 245 864 | 202 440 | 0,19% | Acciones |
| Mirador Capital Partners LP | $17 239 900 | 202 370 | 0,19% | Acciones |
| Tri Locum Partners LP | $16 526 860 | 194 000 | 0,18% | Acciones |
| PFM Health Sciences, LP | $16 329 730 | 191 686 | 0,18% | Acciones |
| Rock Springs Capital Management LP | $16 014 016 | 187 980 | 0,18% | Acciones |
| PRUDENTIAL FINANCIAL INC | $15 933 512 | 187 035 | 0,18% | Acciones |
| DAFNA Capital Management LLC | $14 652 510 | 171 998 | 0,16% | Acciones |
| Ghisallo Capital Management LLC | $14 482 300 | 170 000 | 0,16% | Acciones |
| Impax Asset Management Group plc | $14 056 350 | 165 000 | 0,16% | Acciones |
| Lombard Odier Asset Management (Europe) Ltd | $13 494 096 | 158 400 | 0,15% | Opción de compra |
| KINGDON CAPITAL MANAGEMENT, L.L.C. | $13 383 349 | 157 100 | 0,15% | Acciones |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE | $13 330 276 | 156 477 | 0,15% | Acciones |
| JANE STREET GROUP, LLC | $12 735 905 | 149 500 | 0,14% | Opción de venta |
| SCHRODER INVESTMENT MANAGEMENT GROUP | $12 145 719 | 139 190 | 0,14% | Acciones |
| Retirement Systems of Alabama | $11 962 891 | 140 426 | 0,13% | Acciones |
| MetLife Investment Management, LLC | $11 930 519 | 140 046 | 0,13% | Acciones |
| Polymer Capital Management (HK) LTD | $11 777 943 | 138 255 | 0,13% | Acciones |
| Cinctive Capital Management LP | $11 742 419 | 137 838 | 0,13% | Acciones |
| TUDOR INVESTMENT CORP ET AL | $11 279 156 | 132 400 | 0,13% | Opción de compra |
Informantes de la empresa 52 insiders · 18 directivos · 22 consejeros
| Insider | Rol | Última actividad | Acciones en propiedad | Compras 12m | Ventas 12m | Neto 12m |
|---|---|---|---|---|---|---|
| Sung Lee | EVP, Chief Financial Officer | 1 de julio de 2026 M | 63 221 | 0 | 5 | $-5 695 855 |
| Ching Jaw | SVP Finance & CFO | 6 de marzo de 2023 A | 87 346 | 0 | 0 | $0 |
| Sharon Surrey Barbari | EVP, Finance & CFO | 28 de febrero de 2017 F | 40 323 | 0 | 0 | $0 |
| Fady Ibraham Malik | EVP Research & Development | 18 de agosto de 2026 M | 153 902 | 0 | 22 | $-4 429 370 |
| Andrew Callos | EVP, Chief Commercial Officer | 30 de julio de 2026 M | 58 555 | 0 | 24 | $-15 318 893 |
| Jeffrey Hessekiel | Chief Legal & Admin Officer | 15 de marzo de 2026 A | 107 943 | 0 | 0 | $0 |
| Robert Wong | VP, Chief Accounting Officer | 3 de diciembre de 2024 A | 18 655 | 0 | 0 | $0 |
| Brett A Pletcher | EVP, Chief Legal Officer | 30 de agosto de 2024 A | 33 140 | 0 | 0 | $0 |
| Mark A Schlossberg | SVP - Legal & General Counsel | 15 de marzo de 2022 M | 103 408 | 0 | 0 | $0 |
| David Cragg | Chief HR & Admin Officer | 7 de marzo de 2022 F | 153 233 | 0 | 0 | $0 |
| Caryn Gordon Mcdowell | GC & Chief Compliance Officer | 27 de febrero de 2018 A | 32 548 | 0 | 0 | $0 |
| Peter S Roddy | SVP Finance & CAO | 27 de febrero de 2018 A | 21 520 | 0 | 0 | $0 |
| Bradley Paul Morgan | SVP Drug Discovery & Early Dev | 31 de agosto de 2017 M | 46 441 | 0 | 0 | $0 |
| Bonnie Charpentier | SVP Regulatory & Compliance | 28 de febrero de 2017 A | 29 004 | 0 | 0 | $0 |
| Andrew A Wolff | SVP & CMO | 28 de febrero de 2017 A | 47 255 | 0 | 0 | $0 |
| David J Morgans JR | EVP-Preclinical R&D | 28 de febrero de 2011 A | 42 000 | 0 | 0 | $0 |
| Michael Rabson | SVP Business Dev/Legal & GC | 18 de diciembre de 2009 M | 20 043 | 0 | 0 | $0 |
| Jay K Trautman | VP, Discovery Research | 29 de febrero de 2008 A | 47 896 | 0 | 0 | $0 |
| Robert Arthur Harrington | Consejero | 15 de julio de 2026 A | 21 932 | 0 | 2 | $-248 260 |
| James M Daly | Consejero | 15 de julio de 2026 A | 3 390 | 0 | 0 | $0 |
| Edward M. Kaye MD | Consejero | 15 de julio de 2026 A | 10 434 | 0 | 6 | $-3 544 372 |
| Nancy Wysenski | Consejero | 15 de julio de 2026 A | 33 992 | 0 | 0 | $0 |
| Wendell Wierenga | Consejero | 15 de julio de 2026 A | 35 563 | 0 | 3 | $-1 881 925 |
| John T Henderson | Consejero | 15 de julio de 2026 A | 78 360 | 0 | 2 | $-2 078 525 |
| Lynne B Parshall | Consejero | 1 de junio de 2026 S | 15 784 | 0 | 3 | $-1 000 100 |
| Muna Bhanji | Consejero | 27 de mayo de 2026 A | 26 361 | 0 | 0 | $0 |
| Robert E Landry | Consejero | 27 de mayo de 2026 A | 10 184 | 0 | 0 | $0 |
| Wendall Wierenga | Consejero | 15 de julio de 2025 A | 32 345 | 0 | 0 | $0 |
| COSTA SANTO J | Consejero | 15 de mayo de 2024 A | 20 600 | 0 | 0 | $0 |
| Sandford D Smith | Consejero | 2 de enero de 2024 A | 18 801 | 0 | 0 | $0 |
| Robert Califf | Consejero | 3 de enero de 2022 A | 6 003 | 0 | 0 | $0 |
| GAGE L PATRICK | Consejero | 8 de noviembre de 2021 M | 28 932 | 0 | 0 | $0 |
| Denise Gilbert | Consejero | 20 de mayo de 2015 J | — | 0 | 0 | $0 |
| Stephen M Dow | Consejero | 2 de enero de 2013 A | 1 421 052 | 0 | 0 | $0 |
| James A Spudich | Consejero | 18 de mayo de 2011 A | 180 600 | 0 | 0 | $0 |
| Grant A Heidrich III | Consejero | 3 de enero de 2011 A | 93 755 | 0 | 0 | $0 |
| Michael Schmertzler | Consejero | 3 de junio de 2010 S | 4 340 923 | 0 | 0 | $0 |
| Mark Mcdade | Consejero | 21 de mayo de 2009 A | — | 0 | 0 | $0 |
| Charles J Homcy | Consejero | 22 de mayo de 2008 A | — | 0 | 0 | $0 |
| William J Rutter | Consejero | 29 de abril de 2004 C | 172 413 | 0 | 0 | $0 |
| SEVIN ROSEN FUND VI LP | Propietario del 10% | 29 de abril de 2004 C | 1 615 716 | 0 | 0 | $0 |
| SRB ASSOCIATES VIII LP | Propietario del 10% | 29 de abril de 2004 C | 771 052 | 0 | 0 | $0 |
| SRB ASSOCIATES VII LP | Propietario del 10% | 29 de abril de 2004 C | 650 000 | 0 | 0 | $0 |
| SEVIN ROSEN FUND VIII LP | Propietario del 10% | 29 de abril de 2004 C | 755 631 | 0 | 0 | $0 |
| Robert I Blum | — | 10 de agosto de 2026 M | 377 820 | 0 | 19 | $-9 702 097 |
| Elisabeth Schnieders | — | 28 de febrero de 2017 A | 43 919 | 0 | 0 | $0 |
| James H Sabry | — | 3 de junio de 2010 M | 0 | 0 | 0 | $0 |
| SEVIN ROSEN VII AFFILIATES FUND LP | — | 29 de abril de 2004 C | 24 050 | 0 | 0 | $0 |
| SEVIN ROSEN FUND VII LP | — | 29 de abril de 2004 C | 625 950 | 0 | 0 | $0 |
| SRB ASSOCIATES VI LP | — | 29 de abril de 2004 C | 1 742 951 | 0 | 0 | $0 |
Informantes de las presentaciones SEC Form 3/4/5; neto = solo P/S de mercado abierto
Propiedad de ETFs Mantenido por 84 ETFs
El peso refleja solo las tenencias directas de acciones (N-PORT); los fondos apalancados o basados en derivados pueden tener exposición adicional a swaps no mostrada.
| Fondo | Ponderación | Unidades | A fecha de | Fuente |
|---|---|---|---|---|
| LFSC · RBB Fund, Inc. | 3,16% | 43 268 NS | 31 de mayo de 2026 | N-PORT |
| HRTS · Tema ETF Trust | 2,52% | 17 069 NS | 31 de mayo de 2026 | N-PORT |
| PTH · Invesco Exchange-Traded Fund Trust | 1,81% | 58 136 SH | 8 de agosto de 2026 | Diario |
| FMED · Fidelity Covington Trust | 1,55% | 8 262 NS | 31 de mayo de 2026 | N-PORT |
| GDOC · Goldman Sachs ETF Trust | 1,40% | 3 663 NS | 31 de mayo de 2026 | N-PORT |
| JSMD · Janus Detroit Street Trust | 1,24% | 189 801 NS | 30 de abril de 2026 | N-PORT |
| JSML · Janus Detroit Street Trust | 0,98% | 48 338 NS | 30 de abril de 2026 | N-PORT |
| LABU · Direxion Shares ETF Trust | 0,94% | 76 297 NS | 30 de abril de 2026 | N-PORT |
| IBB · iShares Trust | 0,75% | 874 995 SH | 8 de agosto de 2026 | Diario |
| BBC · ETFis Series Trust I | 0,75% | 4 355 NS | 30 de abril de 2026 | N-PORT |
| IBBQ · Invesco Exchange-Traded Fund Trust … | 0,71% | 7 377 SH | 8 de agosto de 2026 | Diario |
| VTWV · VANGUARD SCOTTSDALE FUNDS | 0,64% | 102 933 SH | 8 de agosto de 2026 | Diario |
| IWN · iShares Trust | 0,62% | 1 099 434 SH | 8 de agosto de 2026 | Diario |
| FNY · First Trust Exchange-Traded AlphaDE… | 0,51% | 41 612 NS | 30 de abril de 2026 | N-PORT |
| BIB · ProShares Trust | 0,47% | 4 553 NS | 31 de mayo de 2026 | N-PORT |
| NUSC · Nushares ETF Trust | 0,47% | 94 565 NS | 30 de abril de 2026 | N-PORT |
| MIDE · DBX ETF Trust | 0,41% | 178 NS | 29 de mayo de 2026 | N-PORT |
| DWAS · Invesco Exchange-Traded Fund Trust … | 0,37% | 21 543 SH | 8 de agosto de 2026 | Diario |
| XJH · iShares Trust | 0,35% | 18 349 SH | 8 de agosto de 2026 | Diario |
| IQSM · New York Life Investments ETF Trust | 0,34% | 16 959 NS | 30 de abril de 2026 | N-PORT |
| VTWO · VANGUARD SCOTTSDALE FUNDS | 0,34% | 761 130 SH | 8 de agosto de 2026 | Diario |
| IWM · iShares Trust | 0,34% | 3 349 200 SH | 8 de agosto de 2026 | Diario |
| IVOG · VANGUARD ADMIRAL FUNDS | 0,33% | 72 343 SH | 8 de agosto de 2026 | Diario |
| VBK · VANGUARD INDEX FUNDS | 0,32% | 1 797 986 SH | 8 de agosto de 2026 | Diario |
| IVOO · VANGUARD ADMIRAL FUNDS | 0,32% | 219 413 SH | 8 de agosto de 2026 | Diario |
| IJK · iShares Trust | 0,32% | 429 311 SH | 8 de agosto de 2026 | Diario |
| ISCG · iShares Trust | 0,32% | 38 968 SH | 8 de agosto de 2026 | Diario |
| IVOV · VANGUARD ADMIRAL FUNDS | 0,31% | 53 623 SH | 8 de agosto de 2026 | Diario |
| IJH · iShares Trust | 0,30% | 4 684 495 SH | 8 de agosto de 2026 | Diario |
| IJJ · iShares Trust | 0,29% | 317 724 SH | 8 de agosto de 2026 | Diario |
| FNX · First Trust Exchange-Traded AlphaDE… | 0,26% | 55 086 NS | 30 de abril de 2026 | N-PORT |
| ITWO · ProShares Trust | 0,25% | 6 062 NS | 31 de mayo de 2026 | N-PORT |
| RSSL · Global X Funds | 0,23% | 51 834 NS | 30 de abril de 2026 | N-PORT |
| PTMC · Pacer Funds Trust | 0,23% | 14 028 NS | 30 de abril de 2026 | N-PORT |
| MVV · ProShares Trust | 0,22% | 4 565 NS | 31 de mayo de 2026 | N-PORT |
| SCHA · SCHWAB STRATEGIC TRUST | 0,21% | 635 330 NS | 31 de mayo de 2026 | N-PORT |
| BKMC · BNY Mellon ETF Trust | 0,20% | 19 862 NS | 30 de abril de 2026 | N-PORT |
| ESML · iShares Trust | 0,20% | 72 711 SH | 8 de agosto de 2026 | Diario |
| SCHM · SCHWAB STRATEGIC TRUST | 0,19% | 356 940 NS | 31 de mayo de 2026 | N-PORT |
| FFSM · FIDELITY COVINGTON TRUST | 0,19% | 37 821 NS | 30 de abril de 2026 | N-PORT |
| VFMO · VANGUARD WELLINGTON FUND | 0,17% | 40 586 SH | 8 de agosto de 2026 | Diario |
| ISCB · iShares Trust | 0,16% | 5 525 SH | 8 de agosto de 2026 | Diario |
| MIDU · Direxion Shares ETF Trust | 0,15% | 2 025 NS | 30 de abril de 2026 | N-PORT |
| UMDD · ProShares Trust | 0,15% | 638 NS | 31 de mayo de 2026 | N-PORT |
| FAD · First Trust Exchange-Traded AlphaDE… | 0,15% | 11 444 NS | 30 de abril de 2026 | N-PORT |
| BBMC · J.P. Morgan Exchange-Traded Fund Tr… | 0,15% | 47 609 NS | 30 de abril de 2026 | N-PORT |
| UWM · ProShares Trust | 0,15% | 4 765 NS | 31 de mayo de 2026 | N-PORT |
| SMDX · Tidal Trust III | 0,15% | 2 868 NS | 30 de abril de 2026 | N-PORT |
| VB · VANGUARD INDEX FUNDS | 0,14% | 3 113 794 SH | 8 de agosto de 2026 | Diario |
| VHT · VANGUARD WORLD FUND | 0,14% | 333 056 SH | 8 de agosto de 2026 | Diario |